Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs Opendoor Technologies Inc (OPEN) Price & Performance

AstraZeneca plcTrade
Opendoor Technologies IncTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs Opendoor Technologies Inc — how do they compare? AstraZeneca plc trades at $159.05 (market cap $250.84B), while Opendoor Technologies Inc trades at $3.6 (market cap $3.36B). The key difference: AstraZeneca plc is far larger — about 74.7× Opendoor Technologies Inc's market cap, and AstraZeneca plc pays a 1.97% dividend while Opendoor Technologies Inc pays none. Which is the better fit depends on your goals.

AZNOPEN
Market Cap
$250.84B$3.36B
Sector
HealthReal Estate
52-Week High
$209.48$10.52
52-Week Low
$147.06$2.42
Enterprise Value
$278.12B$4.43B
Dividend Yield
1.97%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $161.42, up 0.22% today, amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth to $58.74B in 2025 and net income of $10.23B, supported by a P/E of 24.16 and robust profitability margins. Recent news highlights potential talks with Bristol Myers Squibb, though a senior source denied ongoing discussions (Reuters, 2026-08-05).

The outlook is mixed: solid earnings beats and a 47.5% analyst buy rating support upside, but technical weakness and merger uncertainty pose near-term risks. Long-term growth hinges on execution amid competitive and regulatory pressures, with the stock offering value if merger rumors subside and fundamentals prevail.

Opendoor Technologies Inc

Opendoor Technologies (OPEN) trades at $3.485, up 1.16% on the day, but remains in a bearish technical trend with weak fundamentals. Revenue has declined from $15.6B in 2022 to $4.37B in 2025, with persistent net losses and a negative net income margin of -46.74%. Recent Q2 2026 earnings missed expectations, and cash flow volatility adds to operational challenges. The stock faces headwinds from a sluggish housing market and high interest rates, as reflected in negative analyst sentiment and a consensus price target of $3.58.

The outlook for OPEN is cautious due to ongoing losses, competitive pressures, and macroeconomic uncertainty. While the low P/S ratio of 0.95 may attract value seekers, significant execution risk and debt levels pose threats. Investor sentiment is predominantly bearish, with 65% of analysts rating Hold. Recovery hinges on sustainable margin improvement and housing market stabilization, but near-term volatility is expected.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About Opendoor Technologies Inc

Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.

Read more on OPEN